The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis
Open accessAbstract
IMPORTANCE: Minimal residual disease (MRD) refers to the presence of disease in cases deemed to be in complete remission by conventional pathologic analysis. Assessing the association of MRD status following induction therapy in patients with acute lymphoblastic leukemia (ALL) with relapse and mortality may improve the efficiency of clinical trials and accelerate drug development. OBJECTIVE: To quantify the relationships between event-free survival (EFS) and overall survival (OS) with MRD status in pediatric and adult ALL using publications of clinical trials and other databases. DATA SOURCES: Clinical studies in ALL identified via searches of PubMed, MEDLINE, and clinicaltrials.gov. STUDY SELECTION: Our search and study screening process adhered to the PRISMA Guidelines. Studies that addressed EFS or OS by MRD status in patients with ALL were included; reviews, abstracts, and studies with fewer than 30 patients or insufficient MRD description were excluded. DATA EXTRACTION AND SYNTHESIS: Study sample size, patient age, follow-up time, timing of MRD assessment (postinduction or consolidation), MRD detection method, phenotype/genotype (B cell, T cell, Philadelphia chromosome), and EFS and OS. Searches of PubMed and MEDLINE identified 566 articles. A parallel search on clinicaltrials.gov found 67 closed trials and 62 open trials as of 2014. Merging results of 2 independent searches and applying exclusions gave 39 publications in 3 arms of patient populations (adult, pediatric, and mixed). We performed separate meta-analyses for each of these 3 subpopulations. RESULTS: The 39 publications comprised 13 637 patients: 16 adult studies (2076 patients), 20 pediatric (11 249 patients), and 3 mixed (312 patients). The EFS hazard ratio (HR) for achieving MRD negativity is 0.23 (95% Bayesian credible interval [BCI] 0.18-0.28) for pediatric patients and 0.28 (95% BCI, 0.24-0.33) for adults. The respective HRs in OS are 0.28 (95% BCI, 0.19-0.41) and 0.28 (95% BCI, 0.20-0.39). The effect was similar across all subgroups and covariates. CONCLUSIONS AND RELEVANCE: The value of having achieved MRD negativity is substantial in both pediatric and adult patients with ALL. These results are consistent across therapies, methods of and times of MRD assessment, cutoff levels, and disease subtypes. Minimal residual disease status warrants consideration as an early measure of disease response for evaluating new therapies, improving the efficiency of clinical trials, accelerating drug development, and for regulatory approval. A caveat is that an accelerated approval of a particular new drug using an intermediate end point, such as MRD, would require confirmation using traditional efficacy end points.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Gelman, A., Carlin, J. B., Stern, H. S., & Rubin, D. B. (2003) · doi:10.1201/9780429258480 · Cited by 27,276
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009) · doi:10.1002/9780470743386 · Cited by 14,225
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2021) · doi:10.1002/9781119558378 · Cited by 9,799
Cochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Italian Journal of Public Health · doi:10.2427/5768 · Cited by 3,374
Guyot, P., Ades, A., Ouwens, M. J., & Welton, N. J. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-9 · Cited by 2,526
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 913
Borowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., Linda, S., Martin, P. L., Pullen, D. J., Viswanatha, D., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132837 · Cited by 842
Conter, V., Bartram, C. R., Valsecchi, M. G., Schrauder, A., Panzer-Grümayer, R., Möricke, A., Aricò, M., Zimmermann, M., Mann, G., De Rossi, G., et al. (2010) · Blood · doi:10.1182/blood-2009-10-248146 · Cited by 785
Berry, D. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1927 · Cited by 726
Self-citationBrüggemann, M., Raff, T., Flohr, T., Gökbuget, N., Nakao, M., Droese, J., Lüschen, S., Pott, C., Ritgen, M., Scheuring, U., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2708 · Cited by 537
Gökbuget, N., Kneba, M., Raff, T., Trautmann, H., Bartram, C.-R., Arnold, R., Fietkau, R., Freund, M., Ganser, A., Ludwig, W.-D., et al. (2012) · Blood · doi:10.1182/blood-2011-09-377713 · Cited by 493
Vora, A., Goulden, N., Wade, R., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., & Richards, S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70600-9 · Cited by 478
Böttcher, S., Ritgen, M., Fischer, K., Stilgenbauer, S., Busch, R. M., Fingerle-Rowson, G., Fink, A. M., Bühler, A., Zenz, T., Wenger, M. K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9348 · Cited by 460
Bassan, R., Spinelli, O., Oldani, E., Intermesoli, T., Tosi, M., Peruta, B., Rossi, G., Borlenghi, E., Pogliani, E. M., Terruzzi, E., et al. (2009) · Blood · doi:10.1182/blood-2008-11-185132 · Cited by 430
Borowitz, M. J., Wood, B. L., Devidas, M., Loh, M. L., Raetz, E. A., Salzer, W. L., Nachman, J. B., Carroll, A. J., Heerema, N. A., Gastier-Foster, J. M., et al. (2015) · Blood · doi:10.1182/blood-2015-03-633685 · Cited by 362
Self-citationFlohr, T., Schrauder, A., Cazzaniga, G., Panzer-Grümayer, R., van der Velden, V, Fischer, S., Stanulla, M., Basso, G., Niggli, F. K., Schäfer, B. W., et al. (2008) · Leukemia · doi:10.1038/leu.2008.5 · Cited by 361
Walter, R. B., Buckley, S. A., Pagel, J. M., Wood, B. L., Storer, B. E., Sandmaier, B. M., Fang, M., Gyurkocza, B., Delaney, C., Radich, J. P., et al. (2013) · Blood · doi:10.1182/blood-2013-06-506725 · Cited by 360
Self-citationBroglio, K. R., Quintana, M., Foster, M., Olinger, M., McGlothlin, A., Berry, S. M., Boileau, J.-F., Brezden-Masley, C., Chia, S., Dent, S., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.6113 · Cited by 352
Self-citationBeldjord, K., Chevret, S., Asnafi, V., Huguet, F., Boulland, M.-L., Leguay, T., Thomas, X., Cayuela, J.-M., Grardel, N., Chalandon, Y., et al. (2014) · Blood · doi:10.1182/blood-2014-01-547695 · Cited by 330
Chen, I.-M., Harvey, R. C., Mullighan, C. G., Gastier-Foster, J., Wharton, W., Kang, H., Borowitz, M. J., Camitta, B. M., Carroll, A. J., Devidas, M., et al. (2012) · Blood · doi:10.1182/blood-2011-11-394221 · Cited by 245
Self-citationRaff, T., Gökbuget, N., Lüschen, S., Reutzel, R., Ritgen, M., Irmer, S., Böttcher, S., Horst, H.-A., Kneba, M., Hoelzer, D., et al. (2007) · Blood · doi:10.1182/blood-2006-07-037093 · Cited by 240
High-Throughput Sequencing Detects Minimal Residual Disease in Acute T Lymphoblastic Leukemia
Wu, D., Sherwood, A., Fromm, J. R., Winter, S. S., Dunsmore, K. P., Loh, M. L., Greisman, H. A., Sabath, D. E., Wood, B. L., & Robins, H. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003656 · Cited by 237
Self-citationRavandi, F., Jorgensen, J. L., Thomas, D. A., O’Brien, S., Garris, R., Faderl, S., Huang, X., Wen, S., Burger, J. A., Ferrajoli, A., et al. (2013) · Blood · doi:10.1182/blood-2012-11-466482 · Cited by 205
Vilmer, E., Suciu, S., Ferster, A., Bertrand, Y., Cavé, H., Thyss, A., Benoit, Y., Dastugue, N., Fournier, M., Souillet, G., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401960 · Cited by 204
Kang, H., Chen, I.-M., Wilson, C. S., Bedrick, E. J., Harvey, R. C., Atlas, S. R., Devidas, M., Mullighan, C. G., Wang, X., Murphy, M., et al. (2010) · Blood · doi:10.1182/blood-2009-05-218560 · Cited by 196
Self-citationMortuza, F. Y., Papaioannou, M., Moreira, I. M., Coyle, L., Gameiro, P., Gandini, D., Prentice, H. G., Goldstone, A. H., Hoffbrand, A. V., & Foroni, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.1094 · Cited by 192
Shaping of Human Germline IgH Repertoires Revealed by Deep Sequencing
Larimore, K., McCormick, M. W., Robins, H. S., & Greenberg, P. D. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201303 · Cited by 175
Stow, P., Key, L., Chen, X., Pan, Q., Neale, G. A., Coustan-Smith, E., Mullighan, C. G., Zhou, Y., Pui, C.-H., & Campana, D. (2010) · Blood · doi:10.1182/blood-2009-11-253435 · Cited by 159
Zhou, J., Goldwasser, M. A., Li, A., Dahlberg, S. E., Neuberg, D. S., Wang, H., Dalton, V., McBride, K., Sallan, S. E., Silverman, L. B., et al. (2007) · Blood · doi:10.1182/blood-2006-09-045369 · Cited by 137
Pulsipher, M. A., Langholz, B. M., Wall, D. A., Schultz, K. R., Bunin, N., Carroll, W. L., Raetz, E. A., Gardner, S. L., Gastier, J. M., Howrie, D. L., et al. (2014) · Blood · doi:10.1182/blood-2013-10-534297 · Cited by 134
Spinelli, O., Peruta, B., Tosi, M., Guerini, V., Salvi, A., ZANOTTI, M., Oldani, E., Grassi, A., Intermesoli, T., Micò, M. C., et al. (2007) · Haematologica · doi:10.3324/haematol.10965 · Cited by 132
Buccisano, F., Maurillo, L., Gattei, V., Poeta, G. D., Principe, M. I. D., Cox, M. C., Panetta, P., Consalvo, M. I., Mazzone, C., Neri, B., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404313 · Cited by 131
Lee, S., Kim, D.-W., Cho, B.-S., Yoon, J.-H., Sh, S., Yahng, S.-A., Lee, S.-E., Eom, K.-S., Kim, Y.-J., Chung, N.-G., et al. (2012) · Leukemia · doi:10.1038/leu.2012.164 · Cited by 116
Gaipa, G., Cazzaniga, G., Valsecchi, M. G., Panzer‐Grümayer, R., Buldini, B., Silvestri, D., Karawajew, L., Maglia, O., Ratei, R., Benetello, A., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.060426 · Cited by 111
Eckert, C., von Stackelberg, A., Seeger, K., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.010 · Cited by 100
Pane, F., Cimino, G. G., Izzo, B., Camera, A., Vitale, A., Quintarelli, C., Picardi, M., Specchia, G., Mancini, M., Cuneo, A., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403683 · Cited by 97
Stirewalt, D. L., Guthrie, K. A., Beppu, L. W., Bryant, E. M., Doney, K., Gooley, T. A., Appelbaum, F. R., & Radich, J. P. (2003) · Transplantation and Cellular Therapy · doi:10.1016/s1083-8791(03)70011-1 · Cited by 82
Self-citationSutton, R., Shaw, P. J., Venn, N. C., Law, T., Dissanayake, D. R. A., Kilo, T., Haber, M., Norris, M. D., Fraser, C., Alvaro, F., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13142 · Cited by 77
Bowman, W. P., Larsen, E. L., Devidas, M., Linda, S. B., Blach, L. E., Carroll, A. J., Carroll, W. L., Pullen, D. J., Shuster, J. J., Willman, C. L., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.22944 · Cited by 70
Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval
Berry, D. A., & Hudis, C. A. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1293 · Cited by 54
Self-citationKorthals, M., Sehnke, N., Kronenwett, R., Bruns, I., Mau, J., Zohren, F., Haas, R. R., Kobbe, G., & Fenk, R. R. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.07.002 · Cited by 54
Emerging innovations in clinical trial design
Berry, D. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.285 · Cited by 46
Self-citationStirewalt, D. L., Guthrie, K. A., Beppu, L. W., Bryant, E. M., Doney, K., Gooley, T., Appelbaum, F. R., & Radich, J. P. (2003) · Transplantation and Cellular Therapy · doi:10.1053/bbmt.2003.50025 · Cited by 35
Self-citation
Cited by
Gökbuget, N., Dombret, H., Bonifacio, M., Reichle, A., Graux, C., Faul, C., Diedrich, H., Topp, M. S., Brüggemann, M., Horst, H.-A., et al. (2018) · Blood · doi:10.1182/blood-2017-08-798322 · Cited by 858
Malard, F., & Mohty, M. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33018-1 · Cited by 773
Circulating tumor DNA and liquid biopsy in oncology
Cescon, D. W., Bratman, S. V., Chan, S. M., & Siu, L. L. (2020) · Nature Cancer · doi:10.1038/s43018-020-0043-5 · Cited by 600
Stock, W., Luger, S. M., Advani, A. S., Yin, J., Harvey, R. C., Mullighan, C. G., Willman, C. L., Fulton, N., Laumann, K. M., Malnassy, G., et al. (2019) · Blood · doi:10.1182/blood-2018-10-881961 · Cited by 488
Short, N. J., Zhou, S., Fu, C., Berry, D. A., Walter, R. B., Freeman, S. D., Hourigan, C. S., Huang, X., Nogueras Gonzalez, G., Hwang, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4600 · Cited by 390
Self-citation
Metadata
- Authors
- Berry, D. A., Zhou, S., Higley, H., Mukundan, L., Fu, S., Reaman, G. H., Wood, B. L., Kelloff, G. J., Jessup, J. M., & Radich, J. P.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-07-13
- Volume
- 3
- Issue
- 7
- Pages
- e170580
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2613210669
- Cited by
- 599
- References
- 49
- FWCI
- 41.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.